L. H. Belkoff u. a.: An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. In: Int J Clin Pract. 67, April 2013, S. 333–341. doi:10.1111/ijcp.12065. PMID 23521325.
I. Goldstein, A. R. McCullough, L. A. Jones u. a.: A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. In: J Sex Med. 9, 2012, S. 1122–1133. doi:10.1111/j.1743-6109.2011.02629.x. PMID 22248153.
I. Goldstein, L. A. Jones, L. Belkoff u. a.: Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. In: Mayo Clin Proc. 87(9), August 2012, S. 843–852. doi:10.1016/j.mayocp.2012.06.016. PMID 22857780.
J. P. Mulhall, A. L. Burnett, R. Wang u. a.: A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. In: J Urol. 189, 2013, S. 2229–2236. doi:10.1016/j.juro.2012.11.177. PMID 23219537.
R. Wang u. a.: Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. In: J Sex Med. 9, August 2012, S. 2122–2129. doi:10.1111/j.1743-6109.2012.02822.x. PMID 22759639.
L. H. Belkoff u. a.: An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. In: Int J Clin Pract. 67, April 2013, S. 333–341. doi:10.1111/ijcp.12065. PMID 23521325.
I. Goldstein, A. R. McCullough, L. A. Jones u. a.: A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. In: J Sex Med. 9, 2012, S. 1122–1133. doi:10.1111/j.1743-6109.2011.02629.x. PMID 22248153.
I. Goldstein, L. A. Jones, L. Belkoff u. a.: Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. In: Mayo Clin Proc. 87(9), August 2012, S. 843–852. doi:10.1016/j.mayocp.2012.06.016. PMID 22857780.
J. P. Mulhall, A. L. Burnett, R. Wang u. a.: A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. In: J Urol. 189, 2013, S. 2229–2236. doi:10.1016/j.juro.2012.11.177. PMID 23219537.
R. Wang u. a.: Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. In: J Sex Med. 9, August 2012, S. 2122–2129. doi:10.1111/j.1743-6109.2012.02822.x. PMID 22759639.
pharmazeutische-zeitung.de
Avoxa Mediengruppe Deutscher Apotheker GmbH: Tadalafil und Vardenafil. In: Pharmazeutische Zeitung online. Abgerufen am 22. Juli 2017.
